TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00206674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (Leukine)
Description: 6µg/kg SARGRAMOSTIM subcutaneous daily for 8 weeks
Study: NCT02286284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apheresis for extracorporal removal of sFlt-1
Study: NCT01783860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Study: NCT00455923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide
Description: Seretide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flixotide
Description: Flixotide
Study: NCT03224741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary Incentive
Description: Subjects in this condition will be read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information.Iin addition, they will be told that if they will get tested for HIV/AIDS within the next two weeks, they will receive $10 (the US dollar became Ecuador's official currency in 2001).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information
Description: Subjects assigned to this condition are read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information. Then, they are invited to get tested in the next two weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Choice
Description: Subjects in this condition will receive the same information and flyer as in T1; in addition, they are told that they have the opportunity to express their intention to get tested for HIV/AIDS. To this aim, they will be given a sheet of paper and asked to tick one of two boxes. The first box will say I intend to get tested within the next two weeks, and the second will say I will consider getting tested within the next two weeks but I am not ready to commit at this time. They will also be asked to write their initials at the bottom of the sheet, and will be told to keep it. This is a form of soft commitment which has proven effective in other contexts (Bryan et al. 2010).
Study: NCT02985567

Intervention type: OTHER
Intervention: Intraocular pressure evaluation
Description: Intraocular pressure checked with Icare rebound tonometer at 25 minutes after induction, followed by every 10 minutes until sedation was complete.
Study: NCT03501407

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: 1 or 2 blood samples will be collected from the patient.
Study: NCT00206674

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile liquid solution, inactive excipient only subcutaneous daily for 8 weeks
Study: NCT03501407

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: 1 or 2 blood samples will be collected from the patient.

Intervention type: DIAGNOSTIC_TEST
Intervention: skin biopsy
Description: A skin biopsy will be performed on the periphery of the erythema migrans
Study: NCT04450979

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bioactive hydrolysate
Description: Participants given a bioactive vegetable hydrolysate to take one dose each morning and one dose each evening for the duration of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bioactive hydrolysate
Description: Participants given a bioactive vegetable hydrolysate to take one dose each morning and one dose each evening for the duration of the study.
Study: NCT01699399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: water immersion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: water exchange

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: air insufflation
Study: NCT02248584

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C, E and Zinc
Description: Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
Study: NCT04335565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sugar replacements
Description: Participants will receive a solution of stevia before being administered a fixed meal (lunch). Glucose and insulin levels, and Visual analogue scale data will be collected.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sugar replacements
Description: Participants will receive a solution of stevia before being administered a fixed meal (lunch). Glucose and insulin levels, and Visual analogue scale data will be collected.
Study: NCT02860039

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: High dose Trivalent Influenza Vaccine given intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Influenza Vaccine
Description: Standard dose Quadrivalent Influenza Vaccine given intramuscular

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02168205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Capsules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Capsules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Capsules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco
Description: Cigarettes
Study: NCT02269501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise treatment
Study: NCT02328404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50,000 IU vitamin D3
Description: Film-coated tablet Biodal 50,000 IU containing cholecalciferol 50,000 IU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo film-coated tablet of Biodal 50,000 IU
Study: NCT02362646

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MPC Intramyocardial Injection
Description: Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control Solution
Study: NCT03648385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA tablet
Description: DHEA tablet (50 mg) taken by mouth once a day for 18 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo tablet taken by mouth once a day for 18 weeks
Study: NCT03265483

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium glycinate
Description: Oral administration of magnesium glycinate daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of identical-appearing placebo daily for 12 weeks
Study: NCT02428959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amyl Nitrite
Description: Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle; decreases venous ratios and arterial blood pressure; reduces left ventricular work; decreases myocardial oxygen consumption. The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
Study: NCT02275039

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: modified vaccinia virus ankara vaccine expressing p53
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT05073276

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Patient is randomized to the weightbearing group the day after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Patient is randomized to the weightbearing group the day after surgery.
Study: NCT04512391

Intervention type: PROCEDURE
Intervention: Ultrasound guided Erector Spinae Plane Block (ESPB)
Description: Ultrasound guided ESPB is applied at T4 vertebrae level, 3 cm lateral to mid-line where transverse process lies. After identification of transverse process, needle is advanced in plane and real time visualisation on ultrasound screen. When bonny contact is encountered, normal saline is injected for verification of placement, then, 25 ml %0,25 bupivacaine is injected plane between transverse process and erector spinae muscles.
Study: NCT04218175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromobilization exercises
Description: Median nerve neuromobilization (stretching and shifting) was performed. For median nerve stretching; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed. For median nerve shift; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, the participant flexed his wrist and fingers while lateral flexion of his head to the opposite side, and flexed his wrist and fingers while lateral flexion of the head to the same side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromobilization exercises
Description: Median nerve neuromobilization (stretching and shifting) was performed. For median nerve stretching; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, median nerve stretching was performed by extending the participant's head to the opposite side while flexing the wrist and finger. After waiting for 30 seconds in this position, the wrist and head were moved to the neutral position and the participants relaxed. For median nerve shift; The subjects were brought to shoulder depression and 90 degrees of abduction while the dominant side forearms were supination. In this position, the participant flexed his wrist and fingers while lateral flexion of his head to the opposite side, and flexed his wrist and fingers while lateral flexion of the head to the same side.
Study: NCT04475536

Intervention type: DEVICE
Intervention: TANSEI stent
Description: stenting with the TANSEI sirolimus-eluting stent
Study: NCT02803138

Intervention type: DRUG
Intervention: Ombitasvir/paritaprevir/ritonavir
Description: Co-formulated tablet

Intervention type: DRUG
Intervention: Dasabuvir
Description: Tablet

Intervention type: DRUG
Intervention: Ribavirin
Description: Tablet

Intervention type: BEHAVIORAL
Intervention: Patient support program
Description: Supportive services provided to participants included reminder calls, emails, text messages, a Care Coach, and educational/informational materials.
Study: NCT03955718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motherly App
Description: The Motherly app is a behavioral intervention aimed at preventing maternal depression and promoting child development.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational App (Active Control)
Description: An app with educational content about gestation, maternal health and mental health, child development, etc.
Study: NCT03834961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib Sulfate
Description: Given PO or via NG or G tube
Study: NCT03388528

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Residue Diet Intervention
Description: All patients will be provided with a LRD plan (\< 10g fibre per day) for 12 weeks between visits 2 and 3. They will also be supplemented with multivitamin and mineral tablet or liquid (Forceval) to meet nutrient requirements (prescribed as standard care). The dietitian will provide written and oral information about the LRD and weekly telephone calls to assess patient's progress on the diet.
Study: NCT04356092

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2D perfusion digital subtraction angiography of the foot.
Description: 2D perfusion digital subtraction angiography of the foot was performed after infrapopliteal angioplasty and Perfusion Blood Volume (PBV), Mean Transit Time (MTT), and Perfusion Blood Flow (PBF) maps were extracted by analyzing Time-Intensity Curves and signal intensity on the perfused vessel mask.
Study: NCT04262024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cabergoline 1.5-2 mg/week).orally daily for 1 month plus health education
Description: Women with hyperprolactiemia scheduled for cabergoline therapy 1.5-2 mg/week). for one month will be offered health education to help minimize prolactin level(group A)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cabergoline 1.5-2 mg/week).orally daily for 1 month without health education
Description: Women with hyperprolactiemia scheduled for cabergoline 1.5-2 mg/week).for one month will not be offered health education (group B)
Study: NCT01734213

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eriobotyra Japonica Lindley Extract
Description: Eriobotyra Japonica Lindley Extract (1.5g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1.5g/day)
Study: NCT04446117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Supplied as 20-mg tablets; administered orally daily at 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Supplied as 1200 mg/20 mL vials; administered as an IV infusion once every 3 weeks (q3w)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Supplied as 500 mg tablets; administered orally daily at 1000mg with prednisone 5 mg orally bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Supplied as 40 mg capsules; administered orally daily at 160mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Supplied as 5 mg tablets; administered orally bid at 5 mg with abiraterone 1000mg orally daily
Study: NCT02720094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Oral Tablet
Description: 30 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF/FTC tablets
Description: 300 mg/200 mg fixed-dose combination tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF/FTC tablets
Description: 300 mg/200 mg fixed-dose combination tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for TDF/FTC tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for cabotegravir oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for CAB LA
Description: Administered as one 3 mL IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
Study: NCT03531593

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Elastography
Description: Ultrasound elastography is a new, noninvasive technique that can assess the stiffness of the liver by the evaluation of how sound waves propagate through the liver parenchyma.
Study: NCT03189914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-3117
Description: RX-3117 will be administered orally in combination with Abraxane.
Study: NCT03505658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and Behavior
Description: Involves 6-weeks of education related to healthy behaviors, nutrition, and exercise.
Study: NCT02044887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: The characteristics of the PCD and CF and motivation will be evaluated to increase the AF through the (Test Prochaska-Diclemente). For 3 months will receive instructions to perform AF autonomously (walking, preferably in the vicinity of the place of residence). The intervention will be conducted by a professional of the health center so only couples of the intervention group will have knowledge of the specific recommendations of the AFISDEMYF. It is an intervention that has demonstrated its effectiveness in the PEPAF study (large, Sanchez et al. 2009) adapted, designed and implemented by primary care professionals for patients with dementia and for family members who care for them.
Study: NCT00815126

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lysine-ASA Nasal ProvocationTest
Description: Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lysine-ASA Nasal ProvocationTest
Description: Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lysine-ASA Nasal ProvocationTest
Description: Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
Study: NCT00483522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management telephone counseling
Description: Subjects are contacted 7 times in year 1 after discharge from hospital rehabilitation unit and 4 times in year 2. Telephone counseling based on a self-management/problem-solving model is conducted by a research care manager.
Study: NCT01427244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: monoclonal antibody
Study: NCT01621373

Intervention type: DRUG
Group type: OTHER
Intervention: propofol administration
Description: Single IV bolus propofol start at 1 mg/kg. Dose will be adapted based on predefined scoring systems with +/-0.5 mg/kg.
Study: NCT03319043

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chanqin granules
Description: All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation. Patients in treatment group are given additional Chanqin granules 10g three times a day; and analogous for the controlled group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chanqin granules
Description: All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation. Patients in treatment group are given additional Chanqin granules 10g three times a day; and analogous for the controlled group.
Study: NCT03058731

Intervention type: DEVICE
Intervention: Matristem
Description: Paraesophageal hernia repair with MatriStem Surgical Matrix

Intervention type: DEVICE
Intervention: Control
Description: Paraesophageal hernia repair with other biologic mesh
Study: NCT05095480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Red Yeast Rice Pill
Description: Taking Lesstat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo receiving group
Study: NCT01933334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).
Study: NCT02182544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WAL801CL dry syrup

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen fumarate dry syrup

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate dry syrup placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WAL 801 CL dry syrup placebo
Study: NCT04962971

Intervention type: DIETARY_SUPPLEMENT
Intervention: X
Description: exocyan

Intervention type: DIETARY_SUPPLEMENT
Intervention: Y
Description: exocyan

Intervention type: DIETARY_SUPPLEMENT
Intervention: Z
Description: exocyan
Study: NCT02530619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO
Study: NCT03456778

Intervention type: DEVICE
Intervention: Shear Wave Elastography
Description: An ultrasound (US) technique, known as shear wave elastography (SWE), is used to examine structure and biomechanical function. The examination takes place in the ultrasound room at the study site and lasts for approximately 20 minutes.

Intervention type: DEVICE
Intervention: Shear Wave Elastography
Description: An ultrasound (US) technique, known as shear wave elastography (SWE), is used to examine structure and biomechanical function. The examination takes place in the ultrasound room at the study site and lasts for approximately 20 minutes.
Study: NCT02530619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies